Evidence map›Paper›PMID 41255360›Full record

ArticleCombinatorial chemistry & high throughput screening2026

Network Pharmacology and Computational Study to Identify Active Components and Potential Targets of

Yuan Pan, Xiaoyu Zhang, Chao Chen, Chunmei Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuan PanDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210003, China.
Xiaoyu ZhangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210003, China.
Chao ChenDepartment of Emergency, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210003, China.
Chunmei HuDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction

methodsActive compounds and disease targets of P. sibiricum were retrieved from the TCMSP and CTD databases. A PROTEIN-PROTEIN INTERACTION (PPI) network was constructed using the STRING database, and functional enrichment was performed with the clusterProfiler package. A compound-target-pathway network was developed in Cytoscape. Immune infiltration was assessed via CIBERSORT and ESTIMATE algorithms, while ligand-target binding was evaluated by molecular docking and 100-ns molecular dynamics (MD) simulations. In vitro experiments were performed to explore the expression and functions of the key genes.

resultsWe screened 9 active components, 87 putative targets, and 240 HCC-related genes. 20 overlapping targets were used to construct a PPI network. Network analysis identified baicalein and 4 core targets DISCUSSION: P. sibiricum, particularly through baicalein targeting FOS/MMP9/AKT1/ TP53/PTGS2, inhibited HCC development by modulating EMT/angiogenesis pathways and immune milieu. However, these findings required further verification.

conclusionBaicalein was identified as an active compound targeting 5 crucial genes to suppress HCC progression, uncovering a new anti-HCC mechanism of P. sibiricum.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, HepatocellularFlavanonesLiver NeoplasmsNetwork PharmacologyPolygonatumCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein Interaction MapsAntineoplastic Agents, PhytogenicbaicaleinFlavanonesbaicaleinbioactive componentshepatocellular carcinomamolecular dockingPolygonatum sibiricumtumor immune microenvironment.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.